| Titan Pharmaceuticals: Another Step in the Recovery Process VFC submits: Titan Pharmaceuticals (TTNP.PK) announced on Tuesday that the SEC has completed the review of the company's "Form 10 for the re-registration of the company's securities and resumption of its reporting obligations under the Securities Exchange Act of 1934."Titan intends to remain a reporting company from this point forward, according to recent releases from the company.Complete Story » seekingalpha.com |
Cord Blood America Spokesperson to Hold Webinar on Banking Stem Cells at Birth (PR Newswire) Cord Blood America, Inc. is pleased to announce that Natalie Curry, the Company's official spokesperson and medically saved by the first umbilical cord blood collection in the world, will discuss a wide range of topics about cord blood banking live from CBAI's laboratory in Las Vegas. us.rd.yahoo.com |
Keryx Biopharm: Real Moves Yet to Materialize VFC submits: Keryx Biopharmaceuticals (KERX) announced on Wednesday that the FDA has granted Orphan Drug status for perifosine in the treatment of neuroblastoma, a cancer of the nervous system mostly affecting children. There are currently no FDA approved therapies for this condition, according to publicly available information.Positive Phase I data for perifosine in the treatment of this indication was presented at this year's ASCO conference. Complete Story » seekingalpha.com |
Bristol to Buy ZymoGenetics Bristol-Myers Squibb agreed to acquire biotechnology company ZymoGenetics Inc. for $9.75 a share in cash, in a deal valued at about $885 million. online.wsj.com |
NeoStem Buys Cell Therapy Service Company ChinaBio Today submits: NeoStem (NBS) has signed a definitive agreement to acquire Progenitor Cell Therapy, LLC, a US cell therapy service company. NeoStem said the transaction will be immediately accretive to earnings. NeoStem did not address the question of whether it would offer Progenitor's services in China.Progenitor provides its clients with a variety of services, including contract manufacturing, product and process development, consulting, GTP services and national distribution. It played an instrumental role in manufacturing Provenge, Dendreon’s (NYSE: DNDN) autologous cellular immunotherapy, for its clinical trials. The company’s operations are in New Jersey and California. Complete Story » seekingalpha.com |